# Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

> **NCT04293276** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** SHR6390

## Key facts

- **NCT ID:** NCT04293276
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2021-08-23
- **Final completion:** 2023-05
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293276, "Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04293276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*